U.S. Plans to Preserve Licensing Partnership Channel with Chinese Pharma Companies; HK Biotech Sector Surges Over 5%
nashnova research
The U.S. Treasury is drafting rules that would let American pharma companies keep investing in drugs developed by Chinese firms — and Hong Kong's Hang Seng Innovative Drug Index jumped 6.21% in a single session, signaling the policy ceiling on Sino-U.S. drug collaboration may be higher than markets feared.
What exactly did the report say?
Reuters, citing people familiar with the matter: the U.S. Treasury is drafting outbound-investment rules that would preserve American firms' ability to license drugs developed by Chinese companies.
One red line — biotech involving pathogens or technologies that could be weaponized would be excluded.
This means → Washington's approach is not a blanket ban but a risk-tiered framework: ordinary drug partnerships continue; sensitive areas get walled off separately.
The rules are not final and may still change — this is a directional signal, not a done deal.
Why did Hong Kong react so sharply?
On September 21, the Hang Seng Biotech Index rose more than 5% and the Hang Seng Innovative Drug Index surged 6.21%, lifting the sector across the board.
Key movers: Akeso +8.67%, Sino Biopharmaceutical +8%, Innovent Biologics +6%, CSPC Pharmaceutical +6%, Zenas BioPharma (诺诚健华) +5.8%, Hutchmed +3%.
In plain terms = the market's deepest fear was never "how strict will the limits be" — it was "will the door shut entirely." This report says the door stays open, just with conditions attached. Once that tail risk faded, valuations snapped back.
How big is the Sino-U.S. drug-licensing market?
According to GlobalData, nearly half of all drug in-licensing deals by U.S. companies from overseas partners in 2025 came from Chinese firms.
The landmark case: Pfizer announced a partnership with Innovent Biologics in May, covering 12 oncology programs with a potential value of up to $10.5 billion.
Nomura, citing China's National Medical Products Administration, noted that Chinese pharma out-licensing deals hit a record 81 transactions in H1 2026, worth roughly $110 billion in aggregate.
This means → Chinese drugmakers are no longer occasional molecule sellers — they are one of the core suppliers in the global drug-development chain. Cutting this channel would break American pharma's own R&D pipelines too.
Why are investors becoming "immune" to geopolitical risk?
Nomura observed that investors now show "strong immunity" to episodic geopolitical shocks in the sector.
The logic: China's cost-performance edge in drug development is too stark to ignore — early-stage development costs are significantly lower than in the West, and clinical timelines move faster.
In plain terms = pharma companies run on spreadsheets, not political positions. As long as Chinese molecules are cheaper and effective, American firms have every incentive to keep the partnership alive — and policy can't easily override that math.
What should investors watch next?
China's 15th Five-Year Plan has made globalization of pharma and biotech firms a core objective; Nomura expects Sino-U.S. licensing deals to "ride the momentum."
Key variables remain: whether the rules land on schedule, where the final boundaries are drawn (which technologies count as "weaponizable"), and whether the U.S. domestic political cycle shifts direction before implementation.
This reflects a deeper pattern — the Sino-U.S. relationship in biopharma is not simple "decoupling" but competing and depending on each other simultaneously. The policy outcome hinges on which of those two forces proves stronger.
市场有风险，内容仅供研究参考，不构成投资建议。